GlassScriptPhysician profile
Sahar Sherf
NPI 1336567510
$866.13
in general payments reported to CMS, 2019-2025
13 companies · $56.78 in 2025
The $56.78 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.48 · 2020: $66.94 · 2021: $190 · 2022: $124 · 2023: $196 · 2024: $187 · 2025: $56.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $213.51 | 2020-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $175.43 | 2020-2023 | |
| Esperion Therapeutics, INC. | $129.72 | 2023 | Nexlizet, Nexletol |
| Lilly USA, LLC | $107.62 | 2019-2025 | Zepbound, Mounjaro |
| Mannkind Corporation | $46.18 | 2021-2024 | |
| Viiv Healthcare Company | $30.27 | 2019 | |
| Janssen Biotech, INC. | $27.97 | 2020 | |
| Xeris Pharmaceuticals, INC. | $24.35 | 2022 | |
| Glaxosmithkline, LLC. | $23.50 | 2021 | |
| Horizon Therapeutics Plc | $23.35 | 2022 | |
| Vistapharm, INC. | $21.95 | 2021 | |
| Corcept Therapeutics | $21.76 | 2023 | Korlym |
| Tandem Diabetes Care, INC. | $20.52 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahar Sherf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.